BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD

Pfizer to buy Biohaven Pharmaceutical in $11.6 bln deal

Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price.